Ciloa, a French preclinical biotechnology company and spin-off from CNRS and University of Montpellier, is a pioneer in the field of exosomes bioengineered in vivo with membrane and/or cytosolic proteins to develop innovative preventive and therapeutic solutions. Ciloa provides unique expertise and tools to develop high-potential exosomes as a technology platform. Leading candidates (T2D, vaccines) at the regulatory-enabling stage are open for licensing, and more offers will be announced soon.